Abstract 5255
Background
PD-1/PD-L1 blockades have shown promising antitumor activity in clinical trials of advanced nasopharyngeal carcinoma (NPC). Being the most wildly used molecular imaging in clinic, 18F-FDG PET/CT provides multiple information of tumor biology. In this study, we investigated the association of PD-L1 expression with 18F-FDG uptake and clinical features in patients with NPC.
Methods
84 patients were initially histopathologically diagnosed with NPC between December 2016 and March 2019. All tissue specimens and PET/CT images were collected before any treatment. The PD-L1 antibody we used in this investigation was SP263 (Ventana, USA). High PD-L1 expression in tumor cells (TC) or tumor-infiltrating immune cells (TIIC) was defined as ≥ 50% of corresponding cells with membranous staining.
Results
The values of tumor SUVmax and TLG in patients with positive TC PD-L1 expression were significantly higher than those of negative TC PD-L1 expression (SUVmax: 10.3±4.1 vs. 6.9±3.2; P < 0.001; TLG: 77.7±64.5 vs. 35.0±20.5; P < 0.001), while the SUVmax values and TLG in patients with positive TIIC PD-L1 expression is lower than those of negative TIIC PD-L1 expression (SUVmax: 7.0±3.4 vs. 9.7±4.1; P = 0.011; TLG: 29.1±14.4 vs. 71.3±61.2; P = 0.001). Univariate analysis showed that the expression of PD-L1 in TC was associated with tumor T stage (P = 0.044) but not with serum Epstein-Barr virus (EBV) load (P = 0.816). On the other hand, the expression of PD-L1 in TIIC was related to both T stage (P = 0.028) and serum EBV load (P = 0.003). In multivariate logistic regression analysis, PD-L1 expression in TC was positively associated with tumor SUVmax (P = 0.003) and TLG (P = 0.001), while PD-L1 expression in TIIC was negatively associated with SUVmax (P = 0.038) and serum EBV load (P = 0.025). Through the ROC curve, the SUVmax cut-off value of 6.7 and the TLG cut-off value of 41.3 can be used to predict the PD-L1 status in TC with an accuracy of 78.6% and 71.4%, while the SUVmax cut-off value of 7.2 can be used to predict the PD-L1 status in TIIC with an accuracy of 72.6%.
Conclusions
18F-FDG uptake with NPC lesions were positively correlated with PD-L1 expression in TC and negatively correlated with PD-L1 expression in TIIC. 18F-FDG PET / CT imaging may be useful for predicting the PD-L1 status in patients with NPC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5465 - Proof of concept clinical study by US-guided intratumor injection of VCN-01, an oncolytic adenovirus expressing hyaluronidase in patients with pancreatic cancer
Presenter: Manuel Hidalgo
Session: Poster Display session 1
Resources:
Abstract
2555 - A Phase 1a/b first-in-human, open-label, dose-escalation, safety, PK and PD study of TP-0903 in solid tumors
Presenter: John Sarantopoulos
Session: Poster Display session 1
Resources:
Abstract
3533 - First in human phase 1/2a study of PEN-866, a Heat Shock Protein 90 (HSP90) ligand – SN38 conjugate for patients with advanced solid tumors: Phase 1 results
Presenter: Johanna Bendell
Session: Poster Display session 1
Resources:
Abstract
4114 - A Phase I Open-Label, Non-Randomized Study of Recombinant Super-Compound Interferon (rSIFN-co) In Patients with Advanced Solid Tumors
Presenter: Amanda Seet
Session: Poster Display session 1
Resources:
Abstract
2537 - Evaluation of Pharmacodynamic (PD) Biomarkers in Advanced Cancer Patients Treated with Oxidative Phosphorylation (OXPHOS) Inhibitor, OPC-317 (OPC)
Presenter: Jie Qing Eu
Session: Poster Display session 1
Resources:
Abstract
5764 - Pharmacokinetic (PK) assessment of BT1718: A phase 1/2a study of BT1718, a first in class Bicycle Toxin Conjugate (BTC), in patients (pts) with advanced solid tumours
Presenter: Natalie Cook
Session: Poster Display session 1
Resources:
Abstract
2683 - A phase I open label dose escalation trial evaluating VT1021 in patients with advanced solid tumors.
Presenter: Wael Harb
Session: Poster Display session 1
Resources:
Abstract
3609 - Interim Results from Trial of SL-801, a Novel XPO-1 Inhibitor, in Patients with Advanced Solid Tumors
Presenter: Judy Wang
Session: Poster Display session 1
Resources:
Abstract
3485 - Phase 1 Trial of Fruquintinib in Patients with Advanced Solid Tumors: Results of the Dose Escalation Phase
Presenter: Andrea Wang-Gillam
Session: Poster Display session 1
Resources:
Abstract
4085 - A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-601 in Patients with Advanced Solid Tumors
Presenter: Anthony Tolcher
Session: Poster Display session 1
Resources:
Abstract